Benralizumab is a humanized monoclonal antibody to the interleukin-5 (IL-5) receptor alpha which leads to a decrease in production and maturation of eosinophils and is used therapeutically to reduce allergic symptoms in patients with eosinophilic asthma. Benralizumab has not been associated with serum enzyme elevations during therapy or to instances of clinically apparent drug induced liver injury.